Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer

Abbott

Status: Completed

Conditions: Prostatic Neoplasm

Treatments: Drug: leuprolide (Lucrin/Lucrin-Tri-depot)

Study type: Observational

Funder types: Industry

Identifiers

NCT01081873

PMOS-BELG-04-001

Details and patient eligibility

About

Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOT® (Leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms of the Belgian marketing authorization and reimbursement conditions.

Enrollment: 2,717 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with advanced prostate cancer who have been prescribed Lucrin/ Lucrin-Tri-depot or any other treatment with local reimbursement guidelines; Patients willing to consent to data being collected and provided to Abbott Laboratories.

Exclusion criteria

• Contraindications according to the Summary of Product Characteristics (SPC).

Trial design

2,717 participants in 1 patient group

Advanced prostate cancer participants

Description:

Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.

Treatment:

Drug: leuprolide (Lucrin/Lucrin-Tri-depot)